Ebstrocel RDEB therapy advances with regulatory filings
INMB’s Ebstrocel (CORDStrom) is reported to be leading regulatory filings for RDEB, alongside late-stage progress in non-immunosuppressive inflammation therapies and ongoing manufacturing/regulatory milestones.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.